About Us

AnaMar is a privately held, clinical-stage biotech company developing a first-in-class, orally bioavailable, peripheral-acting 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine.

AM1476 is a highly selective small molecule, which offers a unique dual-action potential to treat skin and lung manifestations of systemic sclerosis with a favorable safety profile.

AnaMar has positive results from its Phase I study. AM1476 was safe and well-tolerated in a trial of around 100 healthy volunteers.

We have completed Phase II enabling pre-clinical studies for the initial orphan indication systemic sclerosis.

We are combining our innovative therapeutic platform with biomarkers and genetic analysis to identify those patients most likely to benefit from treatment, using our heritage in diagnostics to ensuring the best outcomes for those with fibrosis.

Team

AnaMar’s leadership team has an experienced track record in discovery, development, and advancement of new medicines.

AnaMar has been in business for 25 years with a heritage as a revenue-generating analytic markers and diagnostics business, which has evolved into a biotech focusing on novel therapies for fibrotic diseases.

Ulf Ljungberg

PhD, CEO

Dr. Ljungberg joined AnaMar in 2015. He has long experience from Life science in executive management, licensing/business development and marketing/sales positions in various countries in big pharma and as CEO of biotech start-ups.

Sam Lindgren

MD, PhD, MBA, CMO

Dr. Lindgren joined AnaMar as Chief Medical Officer in 2021. He brings more than 25 years of big pharma experience of clinical drug development, translational medicine, pharmacovigilance, strategy development and senior leadership roles from AstraZeneca, Novartis, Lundbeck and Novo Nordisk.

Denise Goode

BSc, FCA (ICAEW), MIoD, VP BD

Mrs. Mrs. Goode joined AnaMar in 2015 bringing financial, commercial and industry dealmaking experience. She is a non-executive director of Alligator Bioscience AB and Abliva AB, and CEO of QED Life Sciences Limited. Previously, she served in senior leadership positions with AstraZeneca.

Lars Pettersson

PhD, HEAD OF CHEMISTRY & IP

Dr. Pettersson joined AnaMar in 2011 and is responsible for the medicinal chemistry and intellectual property related activities. He has more than 30 years of drug discovery experience, having served in a number of leadership roles at big pharma and biotech companies. Dr. Pettersson is the inventor of the candidate drug AM1476.

Christina Wenglén

PhD, HEAD OF RESEARCH

Dr. Wenglén joined AnaMar in 2007 and is responsible for the research and pharmacology at AnaMar. She has a PhD in Medical Science and has previously conducted research at Lund University, focusing on extracellular matrix biology and rheumatic diseases.

Helena Arozenius

MSc, HEAD OF DRUG DEVELOPMENT

Ms. Arozenius joined AnaMar in 2005 and is responsible for the development activities. She has substantial experience in project management in early phase development projects.

Board Of Directors

Staffan Encrantz

CHAIRMAN

Mr. Encrantz is the Chairman and CEO of Allegro Investment Inc. and represents the owner of AnaMar. He is a private investor who has led the growth and development of a number of early stage businesses to highly successful realizations.

Marie Encrantz

Ms. Encrantz is an EVP and the CFO of Allegro Investment Inc., the Investment Manager of the owner of AnaMar. She has been working in the Allegro group since 2004 and is mainly responsible for financing, accounting and administration. Before Allegro, she spent 7 years in accounting at a semiconductor manufacturer in Silicon Valley.

Anders Ekblom

MD, PhD, DDS, ASSOCIATE PROFESSOR

Dr. Ekblom has substantial experience from senior positions in the biopharmaceutical industry. He has been the executive vice president of Global Medicines Development at AstraZeneca, and the CEO of AstraZeneca Sweden AB. Currently, he is a board member of a number of life science companies.

Ulf Ljungberg

PhD, CEO

Dr. Ljungberg joined AnaMar in 2015. He has long experience from Life science in executive management, licensing/business development and marketing/sales positions in various countries in big pharma and as CEO of biotech start-ups.